AUG 17, 2026 · JOURNAL ARTICLE
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC
Clinical Cancer Research
A prospective single-arm biomarker study in 31 HCC patients with supportive validation in external trial cohorts, identifying immune predictors of AtezoBev response via rigorous multimodal immunophenotyping, but limited by small primary cohort and surrogate endpoints.
Reported
Baseline circulating γδ T cells a…p=0.006
Baseline circulating γδ T cells a…p=0.02
Intratumoral γδ T signature and r…p<0.01